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Suppression of RAD52 causes synthetic lethality in
BRCA-deficient cells. Yet pharmacological inhibition
of RAD52, which binds single-strand DNA (ssDNA)
and lacks enzymatic activity, has not been demon-
strated. Here, we identify the small molecule 6-hy-
droxy-DL-dopa (6-OH-dopa) as a major allosteric
inhibitor of the RAD52 ssDNA binding domain. For
example, we find that multiple small molecules bind
to and completely transform RAD52 undecamer
rings into dimers, which abolishes the ssDNAbinding
channel observed in crystal structures. 6-OH-Dopa
also disrupts RAD52 heptamer and undecamer ring
superstructures, and suppresses RAD52 recruitment
and recombination activity in cells with negligible
effects on other double-strand break repair path-
ways. Importantly, we show that 6-OH-dopa selec-
tively inhibits the proliferation of BRCA-deficient
cancer cells, including those obtained from leukemia
patients. Taken together, these data demonstrate
small-molecule disruption of RAD52 rings as a prom-
ising mechanism for precision medicine in BRCA-
deficient cancers.
INTRODUCTION
Homologous recombination (HR) is an essential DNA repair
pathway due to its accurate and predominant role in DNA break
repair during S phase and G2 (Li and Heyer, 2008; Moynahan
and Jasin, 2010; Sung and Klein, 2006). Heritable mutations in
HR factors, most notably BRCA1 and BRCA2, cause genome
instability and predispose to breast and ovarian cancer (Lok
and Powell, 2012; Moynahan and Jasin, 2010). BRCA defi-
ciencies are also observed in a variety of other cancers including
lung, prostate, and pancreatic cancers, melanomas, and leuke-
mias (Cramer-Morales et al., 2013; Francis et al., 2010; Mai et al.,Chemistry & Biology 22, 1491–1502009;Wang et al., 2014). BRCA-deficient-like phenotypes due to
spontaneous mutations or defects in HR that are independent of
BRCA1/2 are also commonly observed in cancer cells (Ceccaldi
et al., 2015; McCabe et al., 2006; Turner et al., 2004). Because
HR-defective cells are impaired in their ability to repair DNA
breaks during S phase and G2, DNA damage caused during
replication causes severe growth defects in these cells, with little
or no effect in normal cells. Thus, drugs that induce DNA damage
or further inhibit DNA repair during replication can cause syn-
thetic lethality in BRCA-deficient cells while sparing normal cells
(Farmer et al., 2005; McCabe et al., 2006).
The ability to target BRCA-deficient cells for killing has
received wide attention due to the potential development of
non-toxic drugs for personalized medicine. A notable example
includes poly(ADP-ribose) polymerase 1 (PARP-1) inhibitors,
which cause replication-dependent DNA breaks and thus prefer-
entially kill BRCA-deficient cells (Farmer et al., 2005; McCabe
et al., 2006). Thus far PARP-1 inhibitors, such as the recently
approved drug olaparib, have shown promise in the clinic,
barring some side effects (Kaufman et al., 2015; Lord and Ash-
worth, 2012). However, considering that PARP-1 has wide-
ranging roles in transcription, translation, telomere maintenance,
chromatin, and cellular stress response, in addition to DNA
repair, its inhibition inevitably causes a large number of short-
term, and possibly long-term, side effects in normal cells (Farmer
et al., 2005; Gibson and Kraus, 2012; Ji and Tulin, 2010; Lord and
Ashworth, 2012; Thomas and Tulin, 2013). Identifying and char-
acterizing new drug targets that exclusively perform DNA repair
as a backup to HR during S phase and G2 will lead to the devel-
opment of personalized medicine for BRCA-deficient cancer pa-
tients with a significantly lower risk of side effects.
Previous studies demonstrated that cells deficient in BRCA1/2
or associated proteins in this pathway (PALB2, RAD51B/C/D,
XRCC2/3), combined with a deficiency in recombination factor
RAD52, are synthetic lethal (Chun et al., 2013; Feng et al.,
2011; Lok et al., 2013; Lok and Powell, 2012). Cells and mice
deficient in only RAD52, however, are viable with no apparent
phenotypes (Feng et al., 2011; Lok and Powell, 2012; Rijkers
et al., 1998). Thus, these studies have revealed a new vulnera-
bility in BRCA-deficient cells which may be exploited to target4, November 19, 2015 ª2015 Elsevier Ltd All rights reserved 1491
these cells for killing. For example, drugs that inhibit RAD52 ac-
tivity are likely to cause synthetic lethality in BRCA-deficient cells
in a manner similar to PARP-1 inhibitors, but potentially have no
side effects (Lok and Powell, 2012).
Much of our knowledge of how RAD52 functions has been
derived from studies in the yeast model Saccharomyces cerevi-
siae. For example, yeast Rad52 plays a major role in HR by facili-
tating loading of Rad51 recombinase onto RPA-coated single-
stranded DNA (ssDNA), which is necessary for strand invasion
and subsequent steps of HR (Krogh and Symington, 2004; Liu
and Heyer, 2011). This function is consistent with the ability of
Rad52 to bind ssDNA, RPA, and Rad51. Since Rad52 plays a
prominent role in Rad51 loading, yeasts deficient in Rad52 are
impaired in HR and highly sensitive to genotoxic agents (Krogh
and Symington, 2004). Rad52 in yeast and higher eukaryotes
is also essential for the repair of double-strand breaks (DSBs)
by single-strand annealing (SSA) (Kagawa et al., 2002; Krogh
and Symington, 2004; Singleton et al., 2002). In this pathway,
RAD52 uses sequence microhomology along ssDNA exposed
bynucleaseprocessingofDSBs to recombinebrokenDNA,which
results in chromosomal deletions (Krogh and Symington, 2004).
In contrast to yeast, RAD51 loading in mammalian cells is pri-
marily performedby theBRCApathway,whereasRAD52appears
to play a backup role (Feng et al., 2011; Lok et al., 2013; Lok and
Powell, 2012). For example, previous studies have shown that
suppression of RAD52 expression has little or no effect on HR in
BRCA-proficient cells (Fenget al., 2011; Lok et al., 2013). Yet sup-
pressionofRAD52 inBRCA-deficientcells further reducesHRand
RAD51 loading, and causes synthetic lethality (Feng et al., 2011;
Lok et al., 2013). Hence, these studies suggest that RAD52
might promote the survival of BRCA-deficient cells by facilitating
RAD51-dependent HR. Considering that RAD52 is also essential
for SSA, which functions during S phase, its annealing activity
probably also contributes to the survival of BRCA-defective cells.
Although the exact mechanism by which RAD52 promotes the
survival of BRCA-deficient cells remains unclear, a recent report
showed that its ssDNA binding activity is essential for this role
(Cramer-Morales et al., 2013). Altogether, these studies indicate
that small-molecule inhibitors of the RAD52 ssDNA binding
domain are likely to target BRCA-deficient cells for killing.
The crystal structure of the RAD52 ssDNA binding domain, for
example residues 1–209, has been solved by two groups (Ka-
gawa et al., 2002; Singleton et al., 2002). Remarkably, 11 mono-
mers form an undecamer ring with a positively charged channel
around its outer surface that likely interacts with ssDNA (Kagawa
et al., 2002; Singleton et al., 2002). Although DNA binding motifs
are traditionally considered to be ‘‘undruggable,’’ small-mole-
cule disruption of protein complexes is a promising strategy for
inhibiting multi-subunit DNA binding proteins (Scheuermann
et al., 2013). Here, we identify and characterize a small-molecule
allosteric inhibitor of RAD52 that disrupts ring structures of the
protein and selectively impairs the growth of BRCA-deficient
cancer cells.
RESULTS
Identification of RAD52 Small-Molecule Inhibitors
Since recent studies have shown that the proliferation of
BRCA-deficient cells depends on RAD52 ssDNA binding activity1492 Chemistry & Biology 22, 1491–1504, November 19, 2015 ª2015(Cramer-Morales et al., 2013), we set out to identify inhibitors of
the ssDNA binding domain. A fluorescence polarization (FP)
assay that detects RAD52 ssDNA binding was optimized and
adapted for high-throughput screening as follows (Figure 1A,
left). A 29-nt ssDNA probe conjugated with fluorescein (FAM)
was incubated with increasing concentrations of wild-type
(WT) RAD52, which forms a 323-kDa heptamer ring and
higher-order heptamer ring superstructures (Lloyd et al., 2002;
Stasiak et al., 2000; Van Dyck et al., 1998; Van Dyck et al.,
2001). After 30 min FP was determined, which is inversely pro-
portional to the rotation rate of the ssDNA probe (Figure 1A, mid-
dle). RAD52 binding caused an increase in polarization due to
slowed rotation of the ssDNA probe. FP reactions, with and
without RAD52, performed in 384-well high-throughput format
using a liquid handler resulted in a high Z0 score of 0.82, demon-
strating that the assay was consistent and suitable for high-
throughput screening (Figure 1A, right).
We screened a diverse set of 18,304 drug-like compounds and
the Sigma Lopac collection of 1,280 pharmacologically active
compounds, and identified ten small molecules that consistently
inhibited RAD52 ssDNA binding bymore than 60%and exhibited
a relatively low IC50 (%5 mM) (Figures 1B and 1C). The small
molecules were confirmed by high-performance liquid chroma-
tography-mass spectrophotometry or newly purchased. Small-
molecule inhibition of RAD52 ssDNA binding was confirmed
using an orthogonal electrophoresis mobility shift assay
(EMSA) (Figure 1D). Similarly to previous studies, RAD52 shifted
the ssDNA probe to the wells of the polyacrylamide gel due
to its 323-kDa heptamer ring conformation and tendency
to form higher-order heptamer ring superstructures (Benson
et al., 1998; Lloyd et al., 2002; Van Dyck et al., 1998). As a con-
trol, we showed that these large RAD52-ssDNA complexes were
resolved in an agarose gel as in previous studies (Figure S1)
(Benson et al., 1998). Select compounds that inhibited RAD52
by more than 70% were further analyzed in cells.
Small-Molecule Inhibition of RAD52 Activity in Cells
Weexamined the effects of select small molecules on SSA, which
is one of the main activities of RAD52 (Kagawa et al., 2002; Krogh
and Symington, 2004; Singleton et al., 2002). To measure SSA, a
previously characterized GFP reporter system was used that de-
tects activation of GFP expression as a result of SSA repair of an
I-SceI-inducedDSB (Gunn et al., 2011; Gunn andStark, 2012). As
a control, we demonstrated that suppression of RAD52 via siRNA
inhibited SSA as expected (Figure 2A). Surprisingly, only one of
the small molecules, 6-hydroxy-DL-dopa (6-OH-dopa), a precur-
sor of the catecholaminergic neurotoxin 6-hydroxydopamine,
consistently inhibitedSSA (Figure 2B). The remaining compounds
showed either no effect, slight inhibition, or stimulation of SSA,
which was probably due to off-target effects. As a control, we
showed that the effect of 6-OH-dopa was dose dependent
(Figure 2C). Inhibition of SSA by 6-OH-dopa was additionally
confirmed in vitro (Figure S1), and was dependent on RAD52
expression (Figure S2). We also confirmed that 6-OH-dopa
does not interact with ssDNA (Figure S1). Importantly, we found
that small molecules similar in structure to 6-OH-dopa, including
L-DOPS which is in the same catechol chemical class, failed
to inhibit SSA (Figure 2D) and RAD52 ssDNA binding (Figure S1).
Thus, these data indicate that a specific interaction betweenElsevier Ltd All rights reserved
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Figure 1. Identification of RAD52 Inhibitors by High-Throughput Screening
(A) Schematic of fluorescence polarization (FP) assay (left). Plot showing RAD52 binding to ssDNA probe. KD = 25 nM. Data shown as average ± SD from four
independent experiments (middle). Plot showing 176 high-signal (RAD52 with ssDNA probe) and 176 low-signal (ssDNA probe only) FP control reactions per-
formed in 384-well high-throughput format. Z0 factor = 0.82. mP, millipolarization.
(B) Structures of select identified RAD52 inhibitors.
(C) Plot showing IC50 for RAD52 inhibitors.
(D) Schematic of electrophoresis mobility shift assay (EMSA) (left). Non-denaturing gel of EMSA showing inhibition of RAD52 by 60 mM of indicated small
molecules (middle panels). Plot of EMSA data shown as percent inhibition of RAD52. Data shown as average ± SD from three independent experiments (right).6-OH-dopa and RAD52 is responsible for the observed inhibitory
effects in vitro and in vivo.
We further examined the specificity of 6-OH-dopa for RAD52
in cells by investigating its effects on other DSB repair pathways.
First, we tested whether 6-OH-dopa inhibits HR, which shares
the same upstream DNA damage response and resection path-
ways as SSA. Since HR functions mostly independently of
RAD52 in BRCA-proficient cells, we anticipated that inhibition
of RAD52 would have little effect on HR (Feng et al., 2011; Lok
et al., 2013). Indeed, using a previously characterized HR GFP
reporter (Gunn et al., 2011; Gunn and Stark, 2012), we found
that 6-OH-dopa treatment resulted in little or no reduction in
HR (Figure 2E), and had no effect on HR when RAD52 was
suppressed (Figure S2). Thus, these data are consistent with
the ability of 6-OH-dopa to inhibit RAD52 with a considerableChemistry & Biology 22, 1491–150amount of specificity. In support of this, we found that 6-OH-
dopa had little or no effect on RAD51 (IC50 not determined)
compared with RAD52 (IC50 = 1.1 mM) in vitro (Figure 2F).
6-OH-Dopa also had a significantly higher IC50 (> 10 mM) for
S. cerevisiae RAD59, which shares 31.5% sequence identity
with human RAD52 and performs a similar SSA activity (Figures
2F and S3) (Krogh and Symington, 2004; Petukhova et al., 1999;
Wu et al., 2006). We note that the small molecules that inhibited
HR (RU-0180081, RU-0096909) showed stimulation of SSA,
which is expected, based on the ability of HR to suppress SSA
(Figures 2E and 2B) (Stark et al., 2004; Tutt et al., 2001). To
further analyze the specificity of 6-OH-dopa for RAD52 in cells,
we tested its effect on non-homologous end joining (NHEJ). Us-
ing another previously characterized GFP reporter (Gunn et al.,
2011; Gunn and Stark, 2012), we found that 6-OH-dopa only4, November 19, 2015 ª2015 Elsevier Ltd All rights reserved 1493
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slightly inhibited NHEJ (Figure 2G). Considering that HR and
NHEJ each require a host of proteins involved in nucleic acid
processing, signaling, and protein post-translational modifica-
tion, the ability of 6-OH-dopa to selectively inhibit SSA in cells
demonstrates a considerable amount of specificity of the small
molecule for RAD52 (Ciccia and Elledge, 2010; Deriano and
Roth, 2013; Moynahan and Jasin, 2010). Thus, although 6-OH-
dopa is a catechol and has the potential to interfere with some
assays non-specifically, the exhaustive in vitro and cell-based
data presented herein show that its mechanism on RAD52 is
specific.
We further examined the ability of 6-OH-dopa to inhibit RAD52
activity in cells by testing its effects on RAD52 foci formation at
DNA damage caused by cisplatin and ionizing radiation (Fig-
ure 3). eGFP-RAD52 was stably expressed in BCR-ABL trans-
formed murine hematopoietic 32Dcl3 cells, which are known to
be deficient in BRCA1 (Cramer-Morales et al., 2013; Podszywa-
low-Bartnicka et al., 2014). Previous studies have demonstrated
that eGFP-RAD52 is functional in cells (Essers et al., 2002; Feng
et al., 2011), and we found that the purified protein acts like WT
RAD52 in vitro (Figure S1). The eGFP-RAD52-expressing cells
were incubated with DMSO or 6-OH-dopa and further treated
with cisplatin, which causes intra- and inter-strand cross-links
that arrest replication forks. Consistent with the ability of the
small molecule to inhibit RAD52 ssDNA binding, 6-OH-dopa
suppressed eGFP-RAD52 foci formation in a dose-dependent
manner (Figures 3A and S4). We further investigated the effect
of 6-OH-dopa on eGFP-RAD52 foci in HEK293T cells exposed
to ionizing radiation. The small molecule again decreased the
number of eGFP-RAD52 foci in a dose-dependent manner (Fig-
ures 3B and S4). 6-OH-Dopa also inhibited eGFP-RAD52 foci in
MDA-MB-436 cells complemented with BRCA1 following expo-
sure to ionizing radiation (Figures 3C and S4). Together, these re-
sults demonstrate that 6-OH-dopa effectively inhibits RAD52
ssDNA binding in vivo.
Small-Molecule Dissociation of RAD52-ssDNA
Complexes
We next consideredwhether 6-OH-dopawas capable of dissoci-
ating pre-formed RAD52-ssDNA complexes. Given that RAD52
bound tightly to ssDNA (KD = 25 nM; Figure 1A), we anticipated
that RAD52-ssDNA complexes would be resistant to 6-OH-
dopa treatment. To test this, RAD52-ssDNA complexes were
formed and allowed to reach equilibrium after 30 min of incuba-Figure 2. 6-OH-dopa Selectively Inhibits RAD52-Mediated Recombina
(A) Plot showing SSA in U20S cells treated with scrambled and RAD52 siRNA. Da
test (left). Western blots of protein extracts from U20S cells treated with scramb
(B) Plot showing SSA in U20S cells following treatment with 5 mMof the indicated
with triplicates in each experiment. **p = 0.00154, two-tailed Student’s t test.
(C) Plot showing SSA in U20S cells following treatment with 0, 10, and 20 mM of 6
0.00009, two-tailed Student’s t test.
(D) Plot showing SSA in U20S cells following treatment with 5 mMof the indicated s
alanine; 5, 6-OH-dopa. Data represent mean ± SEM from triplicates. *p = 0.0017
(E) Plot showing HR in U20S cells following treatment with 5 mM of the indicated s
with triplicates in each experiment.
(F) Plots showing percent inhibition of indicated protein as a function of 6-OH-
experiments.
(G) Plot showing NHEJ in U20S cells following treatment with or without 5 mMof 6
triplicates in each experiment.
Chemistry & Biology 22, 1491–150tion. 6-OH-Dopa was then added and FP was measured 2 min
later. Remarkably, the small molecule fully dissociated RAD52-
ssDNA complexes as indicated by a reduction in millipolarization
levels nearly identical to those observed for the DNA control (Fig-
ure 4A). 6-OH-Dopa dissociation of RAD52-ssDNA complexes
was also observed by EMSA (Figure 4B).
The ability of the small molecule to rapidly dissociate RAD52-
ssDNA complexes suggested that it might act as a non-compet-
itive inhibitor. To test this, we investigated whether the inhibitory
activity of the small molecule was diminished by simultaneously
adding a large of excess of ssDNA substrate. Strikingly, the small
molecule continued to inhibit RAD52 in the presence of a 100-
fold excess of the ssDNA substrate (Figure 4C). Hence, these
data suggest that the small molecule binds to a different site
than the ssDNA binding channel, and thus acts a non-competi-
tive inhibitor.
Small-Molecule Disruption of RAD52 Rings
To gain more insight into the mechanism of 6-OH-dopa action,
we examined its interaction with RAD52. Since the small mole-
cule inhibits RAD52 ssDNA binding, we envisaged that it acted
on the ssDNA binding domain (residues 1–209; RAD52 1–209).
X-Ray crystallographic studies demonstrate that the ssDNA
binding domain forms an undecamer ring with a large central
channel (Kagawa et al., 2002; Singleton et al., 2002). The 11
subunits form a symmetrical pinwheel-like conformation with
a positively charged channel circling the outer surface that
likely interacts with ssDNA (Kagawa et al., 2002; Singleton
et al., 2002). We found that the small molecule inhibited RAD52
1–209 with an IC50 (1.6 mM) comparable with that of WT
RAD52 (1.1 mM), indicating that it interacts with the ssDNA bind-
ing domain (Figures 5A and 5B). Isothermal titration calorimetry
(ITC) confirmed that 6-OH-dopa interacts with the ssDNA bind-
ing domain with a KD of 17.7 mM (Figure 5C). Unexpectedly,
these data suggested a stoichiometry of 5.04 small molecules
per RAD52 1–209 ring (Figure 5C). This suggests the possibility
that one small molecule binds to every other subunit around
the ring (Figure 5C), which is plausible based on the slightly
different orientation of subunits (Kagawa et al., 2002; Singleton
et al., 2002). Alternatively, the small molecule may bind at the
interface of every other subunit pair, which would also account
for approximately five binding sites.
Considering that 6-OH-dopa may inhibit RAD52 by acting at
multiple subunit interfaces, we wondered whether the smalltion in Vivo
ta represent mean ± SEM from triplicates. **p = 0.00036, two-tailed Student’s t
led and RAD52 siRNA (right).
small molecules. Data represent mean ± SEM from three separate experiments
-OH-dopa. Data represent mean ± SEM from triplicates. ***p = 0.00039, ****p =
mall molecules. 2, L-DOPS; 3, DL-o-tyrosine; 4, b-(2-hydroxy-4-methylphenyl)
5, two-tailed Student’s t test.
mall molecules. Data represent mean ± SEM from three separate experiments
dopa concentration. Data shown as average ± SEM from three independent
-OH-dopa. Data represent average ± SEM from two separate experiments with
4, November 19, 2015 ª2015 Elsevier Ltd All rights reserved 1495
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Figure 3. 6-OH-dopa Inhibits RAD52 Foci
Formation
(A) Cells stably expressing eGFP-RAD52 were
exposed to cisplatin and 6-OH-dopa. Represen-
tative images of nuclei counterstained with DAPI
(blue) and eGFP-RAD52 (green) (left). Plot showing
quantification of cells with eGFP-RAD52 foci
following treatment with cisplatin and 6-OH-dopa
(right). Data represent mean ± SEM from tripli-
cates. *p = 0.01, **p = 0.007, two-tailed Student’s
t test.
(B) Representative fluorescent images of HEK293T
cells visualizing DAPI stain (blue) and EGFP fluo-
rescence (green) following treatment with ionizing
radiation (IR) (left). Plot showing percent HEK293T
cells with R5 eGFP-RAD52 foci following treat-
ment with IR and 6-OH-dopa (right). Data shown as
average ± SEM from three independent experi-
ments. *p = 0.05, **p = 0.03, two-tailed Student’s
t test.
(C) Representative fluorescent images of MDA-
MB-436 BRCA1 complemented cells visualizing
DAPI stain (blue) and EGFP RAD52 (green)
following treatment with or without IR (left).
Plot showing percent MDA-MB-436 BRCA1
complemented cells with R5 eGFP-RAD52 foci
following treatment with IR and 6-OH-dopa (right).
Data shown as average ± SEM from three inde-
pendent experiments. *p = 0.03, **p = 0.02, two-
tailed Student’s t test.molecule altered the structure or composition of the RAD52
1–209 undecamer ring. To test this, we analyzed the mobility
of RAD52 1–209 in a native gel following incubation with
increasing amounts of the small molecule. Remarkably, 6-OH-
dopa enabled the protein to enter the gel, which appeared as
multiple discrete bands, the smallest of which was in the range
of 50–100 kDa (Figure 5D, left). Western blot analysis of
RAD52 1–209 following native gel electrophoresis confirmed
the identity of the bands as RAD52 1–209 (Figure 5D, right).
Together, these results indicate that 6-OH-dopa dissociates
RAD52 complexes. As a control, we showed that a structurally
similar small molecule, DL-o-tyrosine, which failed to inhibit
RAD52 (Figure S1), had no effect on RAD52 1–209 composition
(Figure S1). We also showed that another potent inhibitor of
RAD52 1–209 (RU-0098062; Figures 1B–1D) had no effect on
the composition of the protein (Figure S1). Thus, these results
clearly show that a specific interaction between 6-OH-dopa
and the ssDNA binding domain facilitates dissociation of
RAD52 complexes.1496 Chemistry & Biology 22, 1491–1504, November 19, 2015 ª2015 Elsevier Ltd All rights rLight scattering was used to confirm
small-molecule dissociation of RAD52
complexes and to determine the size of
the resulting protein species. First, light
scattering was performed under high
salt conditions, similar to the reactions
resolved in native gels. In the absence of
the small molecule, the molecular weight
of RAD52 1–209 was 439 kDa, which
likely includes a mixture of single, double,
and triple undecamer rings (Figure 5E,left). The addition of 6-OH-dopa, however, produced a discrete
48.3-kDa species (Figure 5E, middle) that was not observed in
the buffer or small-molecule controls (Figure S5). We note that
the 439-kDa peak slightly increased to 595.6 kDa, which may
be due to some precipitation of RAD52 1–209 by 6-OH-dopa.
Considering that 48.3 kDa is nearly identical in mass to the
sum of two monomers of RAD52 1–209 (48 kDa), these data
demonstrate that the small molecule dissociates the undecamer
ring into dimers (Figure 5E, right). To confirm this result, we
repeated the light-scattering experiment under low salt condi-
tions, which reduce hydrophobic interactions such as those
that promote RAD52 superstructures. Indeed, under low salt
conditions RAD52 1–209 wasmostly detected at 270 kDa, which
closely corresponds to its undecamer form (263 kDa) (Figure 5F,
left). Addition of the small molecule again produced a 48.3-kDa
species (Figure 5F, middle) that was not observed in the buffer
or 6-OH-dopa controls (Figure S5). Remarkably, under these
conditions, 100% of the undecamers (270 kDa) were converted
into dimers (48.3 kDa), demonstrating that the small molecule iseserved
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Figure 4. 6-OH-dopa Dissociates RAD52-ssDNA Complexes and Acts as a Non-competitive Inhibitor
(A) Schematic of FP assay (top). Plot showing dissociation of RAD52-ssDNA complexes by 30 mM 6-OH-dopa (bottom). Data shown as average ± SD from three
independent experiments. mP, millipolarization.
(B) Schematic of EMSA (top). Non-denaturing gel showing dissociation of RAD52-ssDNA complexes by 30 mM 6-OH-dopa (bottom).
(C) Schematic of EMSA (top). Non-denaturing gel showing 6-OH-dopa (25 mM) inhibition of RAD52 in the presence of excess of Cy3-ssDNA substrate (bottom).more active when hydrophobic interactions are suppressed by
low salt (Figure 5F, right).
Although electron microscopy studies demonstrate that
RAD52WT forms heptamer rings and large heptamer ring super-
structures (Stasiak et al., 2000; Van Dyck et al., 1998, 2001), the
atomic structure of full-length RAD52 has not been solved. Thus,
it remains unknown whether the RAD52 WT heptamer ring pos-
sesses an ssDNA binding channel like that observed in the
RAD52 1–209 undecamer ring. However, considering that 6-
OH-dopa exhibits a comparable IC50 for RAD52 WT (1.1 mM)
and RAD52 1–209 (1.6 mM), the ssDNA binding domain is likely
to have a similar conformation in the heptamer and undecamer
forms. We therefore examined whether 6-OH-dopa had similar
effects on the composition of RAD52 WT heptamer rings.
Indeed, the small molecule enabled RAD52 WT to enter a native
gel as discrete higher molecular weight complexes in a similar
manner as observed for RAD52 1–209 (compare Figures 5G
and 5D). The lower molecular weight complex appeared slightly
larger than 670 kDa, which corresponds to a double heptamer
and is consistent with previous gel filtration studies (Figure 5G)
(Lloyd et al., 2005). The higher molecular weight complexes likely
represent heptamer ring superstructures (Figure 5G). In contrast
to the results obtained with RAD52 1–209, 6-OH-dopa failed to
produce smaller molecular weight complexes from RAD52 WT
(compare Figures 5G and 5D). To more accurately determine
the size of RAD52 WT complexes following incubation with
6-OH-dopa, we analyzed the protein by gel filtration. Similarly
to previous studies, the molecular weight of RAD52 WT in the
absence of 6-OH-dopawas around 670 kDa, which corresponds
to a double heptamer ring (Figure 5H, black line) (Lloyd et al.,
2005). Notably, only a small fraction of the loaded protein
entered the column, which we attribute to the tendency of
RAD52 WT to form large superstructures that are excluded
from the column. Consistent with this interpretation, most of
RAD52 WT failed to enter the native gel in the absence of the
small molecule (Figure 5G). Similar to the results obtained fromChemistry & Biology 22, 1491–150native gel analysis, the small molecule enabled a significantly
higher concentration of RAD52 WT to enter the column as multi-
ple discrete higher molecular weight complexes (Figure 5H, red
line). The smaller peak corresponds to a double heptamer,
whereas the larger peak migrated as larger superstructures,
probably composed of three to four heptamer rings (Figure 5H,
red line). Taken together, these experiments demonstrate that
6-OH-dopa disrupts RAD52 heptamer and undecamer ring su-
perstructures, and further dissociates undecamer rings into
dimers.
Selective Killing of BRCA-Deficient Cells by Small-
Molecule Inhibition of RAD52
Since RAD52 ssDNA binding activity has been shown to be
essential for the survival of BRCA-deficient cells (Cramer-Mo-
rales et al., 2013), we examined whether 6-OH-dopa selectively
reduces the viability of cells harboring mutations in BRCA1/2.
As a control, we tested whether suppression of RAD52 reduced
the viability of the BRCA1-deficient triple-negative breast cancer
cell line MDA-MB-436. Similar to previous studies using other
BRCA1-deficient cells (Lok et al., 2013), we found that suppres-
sion of RAD52 via small interfering RNA (siRNA) (Figure S2)
resulted in reduced viability after a short 3-day time course (Fig-
ure 6A). In contrast, suppression of RAD52 caused a slight in-
crease in the viability of the same cell line complemented with
WT BRCA1 (Figure 6A); scrambled siRNA had negligible effects
on viability (Figure 6A). As a further control, we showed that ola-
parib selectively reduced the viability of the BRCA1-mutated
cells, as expected (Figure 6A). Remarkably, 6-OH-dopa treat-
ment resulted in a nearly identical reduction in viability of the
BRCA1-deficient cells (Figure 6A). 6-OH-Dopa also selectively
halted the proliferation of the Chinese hamster cell line VC8
(Figure 6B) and the pancreatic cancer cell line CAPAN-1 (Fig-
ure 6C), which are both defective in BRCA2 due to truncation
mutations. Similar growth defects were observed following ola-
parib treatment (Figures 6B and 6C), demonstrating that the4, November 19, 2015 ª2015 Elsevier Ltd All rights reserved 1497
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Figure 5. 6-OH-dopa Targets the RAD52 ssDNA Binding Domain and Disrupts RAD52 Rings
(A) Schematic of EMSA (top). Non-denaturing gel of EMSA showing 6-OH-dopa inhibition of RAD52 1–209 (bottom).
(B) Schematic of FP assay (top). Plot showing percent inhibition of RAD52 1–209 ssDNA binding as a function of 6-OH-dopa concentration. IC50 = 1.6 mM. Data
shown as average ± SD from three independent experiments (bottom).
(C) Plot of isothermal titration calorimetry (ITC) data showing 6-OH-dopa interaction with RAD52 1–209. KD = 17.8 mM, n = 5. Model of 6-OH-dopa binding to
RAD52 1–209 (inset).
(D) Silver-stained non-denaturing gel of RAD52 1–209 following incubation with 6-OH-dopa (left). Western blot of non-denaturing gel of RAD52 1–209 following
incubation with 6-OH-dopa (right).
(legend continued on next page)
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ability of 6-OH-dopa to selectively inhibit the proliferation of
BRCA-deficient cells is comparable with olaparib. 6-OH-Dopa
also selectively reduced the viability of the BRCA1-deficient tri-
ple-negative breast cancer cell line HCC1937 (Figure 6D).
The ability of 6-OH-dopa to target BRCA-deficient cells was
further examined in clonogenic survival assays. We observed
that 6-OH-dopa inhibited the survival of BRCA-deficient cell
lines, while having little or no effect on BRCA-proficient cells at
the given doses (Figures 6E and 6F). Considering that previous
studies have revealed BRCA deficiencies in acutemyeloid leuke-
mia (AML) and chronic myelogenous leukemia (CML) (Cramer-
Morales et al., 2013; Podszywalow-Bartnicka et al., 2014), we
examined the ability of 6-OH-dopa to halt the growth of AML
and CML patient cells that were previously identified as express-
ing low levels of BRCA1/2 (Figure S6) (Cramer-Morales et al.,
2013; Podszywalow-Bartnicka et al., 2014). Remarkably, treat-
ment with 6-OH-dopa or olaparib resulted in a similar reduction
in colony formation by BRCA-deficient AML patient cells with lit-
tle effects on AML patient cells expressing normal levels of
BRCA1/2 (Figure 6G). We also observed a significant reduction
in the survival of BRCA1-deficient CML patient cells treated
with 6-OH-dopa (Figure 6H). To rule out the possibility that the
selective killing of BRCA-deficient cells was due to an off-target
effect, we examined the effect of 6-OH-dopa on the viability of
cells deficient in both the BRCA pathway and RAD52. For
example, in the event that 6-OH-dopa selectively halted the pro-
liferation of BRCA-deficient cells by inhibiting a target other than
RAD52, the small molecule would still substantially reduce the
viability of BRCA-deficient cells that lacked RAD52. The small
molecule, however, lost its ability to significantly reduce the
viability of BRCA1-deficient cells when RAD52 expression was
suppressed (Figure 6I) (Figure S2). Thus, these data indicate
that the selective growth inhibition of BRCA-deficient cells by
6-OH-dopa results from its ability to inactivate RAD52.
Small-Molecule Inhibition of RAD52 Causes DNA
Damage and Apoptosis in BRCA-Deficient Cells
Since RAD52 is recruited to DNA breaks caused by replicative
stress (Figure 3A) (Lisby et al., 2001; Wray et al., 2008), the
reduced viability of BRCA-deficient cells due to RAD52 inhibition
is likely caused by insufficient repair of DNA breaks caused by
replication stress. Consistent with this, we observed that 6-
OH-dopa treatment resulted in a substantial increase in DNA
damage indicated by gH2AX foci, which was significantly more
pronounced in BRCA-deficient cells (Figure 6J). We also found
that 6-OH-dopa specifically increased apoptosis in BRCA-defi-
cient cells, indicated by annexin V staining (Figure 6K). Taken
together, our data indicate that in BRCA-deficient cells 6-OH-
dopa inactivation of RAD52 causes cell death due to insufficient
repair of DNA breaks caused by regular replicative stress (Fig-
ure 7A, right). In contrast, 6-OH-dopa inactivation of RAD52 in(E) Plots showing light-scattering data of RAD52 1–209 following incubation with
action on RAD52 1–209 with high salt (right).
(F) Plots showing light-scattering data of RAD52 1–209 following incubation with
action on RAD52 1–209 with low salt (right).
(G) Silver-stained non-denaturing gel of RAD52 WT following incubation with 6-O
(H) Gel-filtration profiles of RAD52 WT following incubation with (red line) and wi
(right).
Chemistry & Biology 22, 1491–150BRCA-proficient cells has little or no effect on cell proliferation
due to efficient HR repair of replication forks by the primary
BRCA pathway (Figure 7A, left).
DISCUSSION
Although previous genetic studies have identified RAD52 as a
potential drug target for personalized medicine in BRCA-defi-
cient cancers (Feng et al., 2011; Lok et al., 2013), it remained un-
knownwhether RAD52 could be inactivated by a small molecule,
which is a necessary step toward therapeutic development.
Here, we identify and characterize 6-OH-dopa as a major allo-
steric inhibitor of RAD52 that selectively halts the growth of
BRCA-deficient cancer cells including those obtained from
AML and CML patients. Our findings validate RAD52 as a thera-
peutic target for precision medicine in BRCA-deficient cancers
and showcase a novel allosteric mechanism of inhibition.
Although we initially identified multiple inhibitors of RAD52
in vitro, only 6-OH-dopa consistently inhibited SSA in cells while
having minimal effects on HR and NHEJ. Considering that HR
and NHEJ each require a host of proteins involved in nucleic
acid processing, signaling, and post-translational modifications,
these data show that 6-OH-dopa exhibits a considerable amount
of specificity for RAD52 in cells. Consistent with this, 6-OH-dopa
had no effect on RAD51, which forms a similar heptamer ring
structure with nearly identical dimensions as RAD52 (Shin
et al., 2003). Intriguingly, this characteristic ring shape is com-
mon among replication and repair proteins including the proto-
typical RecA recombinase (Kagawa et al., 2002; Patel and Picha,
2000; Shin et al., 2003; Singleton et al., 2002; Stasiak et al., 2000;
Yu and Egelman, 1997). 6-OH-dopa, however, had very little ef-
fect on RecA (Figure S1) and exhibited a 10-fold higher IC50 for
yeast Rad59, which shares 31.5% sequence identity with
RAD52. Thus, the small molecule also showed a considerable
amount of specificity for RAD52 in vitro. Importantly, 6-OH-
dopa inhibited RAD52 foci in multiple cell lines, which unequivo-
cally demonstrates its ability to inactivate RAD52 in vivo. Thus,
although 6-OH-dopa is a catechol and has the potential to inter-
fere with some assays non-specifically, the in vitro and cell data
presented herein show that its mechanism on RAD52 is specific.
We discovered an unprecedented allosteric mechanism
whereby multiple small molecules bind to RAD52 undecamer
rings and promote their dissociation into dimers. To our knowl-
edge, such a dramatic molecular transformation induced by a
small molecule has never been reported. Considering that the
putative ssDNA binding channel observed in crystal structures
is constructed from all 11 subunits and encircles the entire unde-
camer ring (Kagawa et al., 2002; Singleton et al., 2002), small-
molecule dissociation of the ring is certain to abolish the ssDNA
binding channel. Since a different potent inhibitor of RAD52
(RU-0098062) failed to dissociate the undecamer, the allosteric(right) and without (middle) 6-OH-dopa with 1 M NaCl. Model of 6-OH-dopa
(middle) and without (left) 6-OH-dopa with 0.15 M NaCl. Model of 6-OH-dopa
H-dopa (left).
thout (black line) 6-OH-dopa (left). Model of 6-OH-dopa action on RAD52 WT
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Figure 6. 6-OH-dopa Selectively Inhibits the Growth of BRCA-Deficient Cells
(A–D) Plots showing relative viability of BRCA proficient (black) and deficient (gray) cells following treatment with 20 mM (A), 75 mM (B), 10 mM (C), and 5 mM (D) 6-
OH-dopa, 20 mM olaparib (C), or indicated siRNA. Data shown as average ± SEM from triplicates. Two-tailed Student’s t test: (A) ****p = 0.0008, *p = 0.02, **p =
0.005; (B) ***p = 0.0002, *p = 0.03; (C) *p = 0.01, *p = 0.01; (D) *p = 0.05.
(E–H) Plots showing clonogenic survival of indicated BRCA-proficient and -deficient cells following treatments with 6-OH-dopa or olaparib. Data shown as
average ± SEM from three independent experiments. Data points in (G) and (H) represent three different patient cells pooled together. In (F) *p = 0.03, two-tailed
Student’s t test.
(legend continued on next page)
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A B
C
Figure 7. Models of Small-Molecule Inhibi-
tion of RAD52
(A) Models of 6-OH-dopa action. X = DNA damage.
(B) Model of small-molecule disruption of RAD52
undecamers.
(C) Models of small-molecule disruption of RAD52
WT heptamer superstructures (left) and stacked
heptamer superstructures (right).mechanism exhibited by 6-OH-dopa is clearly very specific.
Small-molecule inhibition of Mre11 ssDNA binding by an allo-
steric mechanism has also been reported, demonstrating the
success of this inhibitory method (Shibata et al., 2014).
Since our data suggest that five small molecules interact with
the undecamer, we propose a model whereby one small mole-
cule binds to every other subunit interface (Figure 7B). This
scheme would account for approximately five small-molecule
binding sites and provide a plausible mechanism by which 6-
OH-dopa induces such a dramatic conformational change. For
example, we propose that 6-OH-dopa binds to a region near
the subunit interface that is critical for ring formation. This is sup-
ported by our data showing that the small molecule completely
transforms undecamers into dimers when hydrophobic interac-
tions are reduced by low salt. Such an interaction may induce
a conformational change that inactivates ssDNA binding (Fig-
ure 7B). A total of five small-molecule binding events at alter-
nating interfaces may then trigger dissociation of RAD52 rings
into dimers (Figure 7B). In support of this model, previous studies(I) Plots showing viability of BRCA1-deficient MDA-MB-436 cells following transfection with scrambled (bla
without 6-OH-dopa. Data shown as average ± SEM from triplicates. *p = 0.0004, two-tailed Student’s t test
(J) Plots showing percent increase in gH2AX foci in BRCA1-proficient (black) and -deficient (gray) MDA-MB-4
Percent increase was determined from the number of nuclei with greater than five gH2AX foci. Data shown
iments. Cell images show DAPI staining (blue) and gH2AX foci (green) (right). **p = 0.002, ***p = 0.0078, two
(K) Plots showing percent of BRCA2-deficient (gray; VC8) and BRCA2-proficient (black; V79) cells positive for
0.01, **p = 0.003, two-tailed Student’s t test (left). Plots showing percent of BRCA1-deficient (gray) and BR
annexin V following treatment with 6-OH-dopa (right).
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in ssDNA binding also contribute to oligo-
merization or proper folding of the protein
(Lloyd et al., 2005). Moreover, residues
within the ssDNA binding domain pro-
mote self-association of RAD52 proteins
in cells (Shen et al., 1996). Thus, 6-OH-
dopa disruption of this region may also
explain its ability to dissociate super-
structures of the protein. A co-crystal
structure of RAD52 1–209 bound to 6-
OH-dopa is needed to identify the precise
binding site.
Intriguingly, 6-OH-dopa exhibited a
31% lower IC50 for RAD52 WT (1.1 mM)
compared with RAD52 1–209 (1.6 mM),
indicating that fewer small molecules are
required to inhibit the WT protein. Indeed,
these data are consistent with the fact
that RAD52 WT is composed of 36%
fewer subunits than RAD52 1–209 and
suggest that 36% fewer small molecules, for example approxi-
mately three, bind the heptamer, presumably at alternating sub-
unit interfaces (Figure 7C, left). Since 6-OH-dopa precipitated
RAD52 WT at high concentrations, we were unable to determine
the number of binding sites by ITC.
Importantly, we found that 6-OH-dopa also altered the
composition of RAD52 WT, which suggests that it induces a
conformational change similar to that for RAD52 1–209. For
example, 6-OH-dopa enabled RAD52 WT to enter a native gel
as multiple discrete protein complexes in a manner similar to
RAD52 1–209. Since a previous report claimed that large
RAD52 heptamer ring superstructures prohibit RAD52 WT from
entering gel filtration columns (Van Dyck et al., 1998), we exam-
ined whether the small molecule affected the gel filtration profile
of RAD52 WT. Indeed, 6-OH-dopa enabled a significantly higher
concentration of RAD52 WT to enter the column as superstruc-
tures and double heptamers. The small molecule, however,
showed no evidence of dissociating heptamer rings into smaller
complexes, which suggests that the C-terminal region of RAD52ck) or RAD52 (white) siRNA and treatment with or
.
36 cells following treatment with 6-OH-dopa (left).
as average ± SEM from three independent exper-
-tailed Student’s t test.
annexin V following treatment with 6-OH-dopa. *p =
CA1-proficient (black) HCC1937 cells positive for
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WT contributes to ring formation or stability. Together, these
data demonstrate that 6-OH-dopa disrupts large superstruc-
tures of RAD52 heptamer rings that are normally excluded
from native gels and gel filtration columns (Figure 7C, left). Since
a double heptamer was the smallest form of RAD52WTdetected
by gel filtration, the possibility exists that RAD52 WT forms
stacked double heptamers such as RAD51 (Figure 7C, right)
(Shin et al., 2003). This modified model would explain why 6-
OH-dopa is unable to fully disrupt these structures. Given that
RAD52 superstructures and high-density RAD52 repair centers
have been shown to promote DSB repair in vitro and in vivo
(Lisby et al., 2001, 2003; Lloyd et al., 2002), respectively, and hu-
man RAD52 has been shown to self-associate in cells (Shen
et al., 1996), the ability of the small molecule to disrupt heptamer
ring superstructures likely contributes to its inhibitory effect
in vivo.
Lastly, we demonstrated that 6-OH-dopa selectively halts the
growth of a variety of BRCA-deficient cancer cells. For example,
6-OH-dopa treatment caused significant growth defects in
BRCA1-mutated triple-negative breast cancer cell lines, but
had little or no effect in the same cell lines complemented with
WT BRCA1. Small-molecule growth inhibition of BRCA2-defi-
cient cells, including the CAPAN-1 pancreatic cancer cell line,
was also observed. Importantly, 6-OH-dopa also selectively
halted the proliferation of BRCA-deficient AML and CML patient
cells. Moreover, the small molecule caused a growth defect
in these and other BRCA-deficient cells similar to that caused
by olaparib, which was recently approved by the Food and
Drug Administration. Hence, these data suggest that pharmaco-
logical inhibition of RAD52 may prove to be a successful alter-
native for treating BRCA-deficient cancers. Finally, we showed
that 6-OH-dopa caused an increase in DNA damage and
apoptosis in BRCA-deficient cells. Considering that RAD52 is
heavily recruited to stalled replication forks (Figure 3A) (Lisby
et al., 2001;Wray et al., 2008), our data support amodel whereby
6-OH-dopa selectively kills BRCA-deficient cells by preventing
RAD52 repair of DNA breaks caused by replication stress
(Figure 7A).
In summary, our results demonstrate small-molecule disrup-
tion of RAD52 rings as a promising mechanism for precision
medicine in BRCA-deficient cancers. Since RAD52 acts as a
backup DNA repair factor in normal cells and RAD52 null mice
show no major phenotypes, we anticipate that pharmacological
inhibition of RAD52 in patients will enable selective killing of
BRCA-deficient cancer cells while minimizing the risk of side ef-
fects in normal cells.
SIGNIFICANCE
Tumor suppressor proteins BRCA1 and BRCA2, which play
major roles in HR and genome maintenance, are mutated
in subsets of ovarian and breast cancers, and such inactivat-
ing BRCA mutations strongly predispose women to breast
and ovarian cancer. Since BRCA-deficient cells are defec-
tive in HR, they are highly susceptible to drugs that cause
DNA damage or suppress DNA repair. Therefore, BRCA-
deficient cancers can be specifically targeted for killing via
so-called precision medicines. Because suppression of the
backup recombination factor RAD52 has been shown to1502 Chemistry & Biology 22, 1491–1504, November 19, 2015 ª2015cause synthetic lethality in BRCA-deficient cells, RAD52 is
a promising drug target for precision medicine in HR-defec-
tive cancers. Here, we identify and characterize 6-OH-dopa
as an effective small-molecule inhibitor of RAD52 in vitro
and in cells. Unexpectedly, 6-OH-dopa acts via an allosteric
mechanism, whereby it dimerizes undecamer rings of the
RAD52 ssDNA binding domain whose activity is essential
for the survival of BRCA-deficient cells. 6-OH-dopa also dis-
rupts superstructures of full-length RAD52 heptamer rings,
suppresses RAD52 foci formation at DNA damage, and
selectively inhibits RAD52-mediated recombination in cells.
Consistent with its ability to inhibit RAD52, 6-OH-dopa
selectively kills BRCA-deficient cancer cells including those
obtained from leukemia patients. These findings indicate
that RAD52 is a ‘‘druggable’’ target, and suggest that
small-molecule disruption of RAD52 rings may be an effec-
tive form of precision medicine for BRCA-deficient cancers.
EXPERIMENTAL PROCEDURES
Protein Purification
RAD52 WT
A histidine-tagged RAD52 WT expression vector (pFB581) (Benson et al.,
1998) was transformed into Rosetta2(DE3)/pLysS cells (Stratagene). Freshly
grown colonies were resuspended in 16 2.8-l Fernbach flasks each contain-
ing 1 l of LB broth supplemented with 100 mg/ml ampicillin and 34 mg/ml chlor-
amphenicol. The flasks were shaken at room temperature until the optical
density at 600 nm reached 0.5, then 0.8 mM isopropyl b-D-1-thiogalactopyr-
anoside was added for an additional 4 hr. The biomass was then collected by
centrifugation and stored at 80C. Frozen pellets were thawed on ice and
resuspended in lysis buffer (25 mM Tris-HCl [pH 7.5], 500 mM NaCl, 10%
[v/v] glycerol, 10 mM imidazole [pH 8], 0.05% [v/v] NP-40 substitute [Thermo
Scientific], 2 mM DTT, 10 mM PMSF, and Complete cocktail protease inhib-
itors [Roche]). Resuspended cells were sonicated on ice with constant stir-
ring, then spun down twice at 35,000 rpm for 30 min at 4C. The clarified
cell lysate was loaded onto a 5-ml His-Trap column (GE Lifesciences), then
washed in the following steps: 20 column volumes (CV) of lysis buffer, 10
CV of lysis buffer with 30mM imidazole, 10 CV of lysis buffer with 60mM imid-
azole, and 5 CV of lysis buffer with 80 mM imidazole. The bound protein was
eluted in two steps with 200 and 500 mM imidazole, respectively, in buffer
containing 25 mM Tris-HCl (pH 7.5), 500 mM NaCl, 10% (v/v) glycerol,
0.005% (v/v) NP-40 substitute, and 1 mM DTT. Fractions containing RAD52
were pooled, dialyzed against buffer A (25 mM Tris-HCl [pH 7.5], 75 mM
NaCl, 10% glycerol, 1 mM DTT, and 0.001% NP-40), then loaded onto a
5-ml Q-Sepharose column and washed with the same buffer. The bound pro-
tein was then eluted in six steps of 1 CV each with buffer A containing
increasing NaCl concentration as follows: 100, 125, 150, 200, 250, and
300 mM. Fractions containing pure RAD52 were dialyzed against storage
buffer (25 mM Tris-HCl [pH 7.5], 100 mM NaCl, 10% glycerol, and 1 mM
DTT). RAD52 WT was concentrated to 2.5 mg/ml and stored in aliquots at
80C. All steps were performed at 4C. RAD52 1–209 was purified as
described (Singleton et al., 2002).
High-Throughput Screening
2 ml of 350 nM RAD52 WT was added to 384-well plates (Greiner Bio-One)
containing 16 ml of buffer B (31.3 mM Tris-HCl [pH 7.5], 1.25 mM DTT,
31.3 mM NaCl, 0.013% NP-40, 0.63 mM MgCl2, and 0.13 mg/ml BSA)
and 18.75 mm of individual compounds from a highly diverse 18,304
small-molecule library and the Sigma Lopac collection. 2 ml of 100 nM
FAM-conjugated ssDNA (RP316FAM) was then added and plates were
centrifuged at 1,000 rpm for 30 s. After at least 30 min of incubation, FP
was determined using a BioTek plate reader. High- and low-signal controls
included and lacked RAD52, respectively. Reactions were performed at
room temperature, and components were added using a Thermo MultiDrop
Combi liquid handler.Elsevier Ltd All rights reserved
IC50 Determination
40 nM RAD52 WT, 85 nM RAD52 1–209, 280 nM RAD51, or 300 nM RAD59
was mixed with reaction buffer C (25 mM Tris-HCl [pH 7.5], 1 mM DTT,
25 mM NaCl, 0.01% NP-40, 0.5 mM MgCl2, and 0.1 mg/ml BSA), 10 nM
FAM-conjugated ssDNA (RP316FAM), and indicated amounts of 6-OH-dopa
in a total volume of 20 ml, then incubated at room temperature for 30 min. Re-
actionswith RAD51 additionally contained 1mMATP. FPwas then determined
using a Clariostar (BMG Labtech) or BioTek plate reader. IC50 was determined
by calculating the concentration of 6-OH-dopa required to inhibit ssDNA bind-
ing by 50% based on FP.
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